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Abstract 23 
Patients with stable chronic obstructive pulmonary disease (COPD) frequently exhibit 24 
unintentional accentuated peripheral muscle loss and dysfunction. Skeletal muscle mass in 25 
these patients is a strong independent predictor of morbidity and mortality. Factors including 26 
protein anabolism/catabolism imbalance, hypoxia, physical inactivity, inflammation, and 27 
oxidative stress are involved in the initiation and progression of muscle wasting in these 28 
patients.  29 
Exercise training remains the most powerful intervention for reversing, in part, muscle 30 
wasting in COPD. Independently of the status of systemic or local muscle inflammation, 31 
rehabilitative exercise training induces up-regulation of key factors governing skeletal muscle 32 
hypertrophy and regeneration. However, COPD patients presenting similar degrees of lung 33 
dysfunction do not respond alike to a given rehabilitative exercise stimulus. In addition, a 34 
proportion of patients experience limited clinical outcomes, even when exercise training has 35 
been adequately performed. Consistently, several reports provide evidence that the muscles 36 
of COPD patients present training-induced myogenic activity resistance as exercise training 37 
induces a limited number of differentially expressed genes, which are mostly associated with 38 
protein degradation.  39 
This review summarises the nature of muscle adaptations induced by exercise training, 40 
promoted both by changes in the expression of contractile proteins and their function 41 
typically controlled by intracellular signalling and transcriptional responses. Rehabilitative 42 
exercise training in COPD patients induces skeletal muscle mechanosensitive signalling 43 
pathways for protein accretion and its regulation during muscle contraction. Exercise training 44 
also induces synthesis of myogenic proteins by which COPD skeletal muscle promotes 45 
hypertrophy leading to fusion of myogenic cells to the myofibre. Understanding of the 46 
biological mechanisms that regulate exercise training-induced muscle growth and 47 
regeneration is necessary for implementing therapeutic strategies specifically targeting 48 
myogenesis and hypertrophy in these patients. 49 
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Introduction 56 
COPD is the fourth leading cause of death worldwide and is projected to be the third most 57 
common cause of death by 2020 (1). Cigarette smoke constitutes the major preventable risk 58 
factor, resulting in a progressive proteolytic, inflammatory and vasoactive response that leads 59 
to emphysema, small airway obstruction and pulmonary hypertension. The oxidative stress 60 
imposed by cigarette smoking together with systemic inflammation and hypoxia are 61 
important contributors to pathogenesis of skeletal muscle wasting and dysfunction and have 62 
been previously extensively reviewed (2-4). Skeletal muscle wasting is an important systemic 63 
effect of the disease and a strong independent predictor of mortality (5-7). This unintentional 64 
accentuated skeletal muscle wasting is frequently associated with altered muscle structure 65 
(fiber size, fiber type distribution, capillary density and metabolic capacity) and dysfunction 66 
(decreased strength and endurance). While the magnitude of the alterations varies 67 
substantially across individuals, some degree of muscle wasting affects all individuals during 68 
ageing. Age-related defects in protein metabolism have been proposed to be causally 69 
involved in this muscle loss (8). These changes are attributed to both inactivity- and age-70 
related alterations in protein synthesis and degradation, indicating complex 71 
pathophysiological phenomena involving both structural changes to the muscle fibres, as well 72 
as the enzymatic machinery that controls metabolism. Independently of the factors promoting 73 
muscle wasting in COPD, regular physical exercise remains the most potent available 74 
treatment option for reversing, in part, locomotor muscle wasting and dysfunction in COPD 75 
(9). Indisputably, exercise training promotes a range of beneficial adaptations in the skeletal 76 
muscle including increased capilarization, fibre type plasticity, hypertrophy and function. 77 
However, exercise training induced muscle benefits are certainly much smaller in COPD 78 
patients compared to age matched controls. In addition, not all COPD patients respond 79 
adequately to exercise stimulus, even when exercise training is properly performed (10, 11). 80 
An improved understanding of molecular mechanisms of exercise induced adaptations in 81 
COPD and healthy individuals will be valuable to inform future directions to address the 82 
issues on resistance to exercise-induced adaptations in COPD.  83 
 84 
Effect of prescribed exercise training to skeletal muscle adaptation in COPD  85 
 86 
Exercise training is a mechanical stimulus that consists of repeated, episodic bouts of muscle 87 
contraction promoting functional adaptation and remodelling not only to the skeletal muscle, 88 
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but also to various systems in our body (12, 13). Exercise promotes a range of adaptations 89 
that is beyond the musculoskeletal system  promoting general health(14). Briefly, in parallel 90 
with neural signals to the skeletal muscle contraction, powerful neural feed-forward signals to 91 
the respiratory, cardiovascular, metabolic and hormonal systems are produced. In response to 92 
exercise training, COPD patients demonstrate reduction in dyspnea sensations, improvements 93 
in exercise capacity and quality of life (9).  94 
 95 
Skeletal muscle adaptations are dependent on the intensity and duration of the exercise 96 
training performed (15). High intensity exercise training (Wpeak ≥80%) is generally 97 
described to promote improvement in exercise capacity. However, COPD patients with 98 
limited ventilatory capacity are usually unable to sustain high intensities for sufficiently long 99 
periods. Taking into consideration COPD patients exercise capacity, a number of studies have 100 
been performed employing a varied combination of exercise modalities/training, program 101 
duration and intensity. Usually, the duration of an exercise training programme is set from 8 102 
to 12 weeks and as frequent as 3 times per week. Combination of high intensity aerobic and 103 
resistance exercise is described to promote quantifiable muscle hypertrophy in COPD (16, 10, 104 
17, 11). Conversely, exercise training of lower intensity (Wpeak ≤ 60%) was found unable to 105 
promote quantifiable changes in muscle hypertrophy and fibre type distribution (18, 19). 106 
Therefore, programmes incorporating high intensity exercise training are more likely to 107 
induce quantifiable skeletal muscle adaptations.  108 
 109 
Different modes of exercise such as endurance- and resistance–based are known to stimulate 110 
variable but specific skeletal muscle adaptations, leading to muscle endurance and strength 111 
respectively (15). Aerobic/endurance exercise training enhances mitochondrial protein 112 
content and oxidative capacity of trained myofibers, improving insulin sensitivity and skeletal 113 
muscle metabolic function (20). Whereas, resistance training increases myosin-heavy-chain 114 
gene transcripts and synthesis rate of muscle proteins promoting strength (15). When 115 
comparing different modalities of exercise prescribed to healthy sedentary people, Robinson 116 
et al (21) observed that high intensity interval training (HIIT) enhanced more 117 
comprehensively changes such as aerobic capacity, mitochondria respiration and lean body 118 
mass (21). HIIT training simultaneously promoted endurance- and resistance–based training 119 
skeletal muscle adaptations, that promoted changes in transcription and translation regulation 120 
of muscle growth and mitochondrial pathways (21). HIIT reversed age-related proteome, 121 
particularly of mitochondrial proteins. But both resistance training and HIIT increase proteins 122 
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involved in translational machinery. HIIT exercise involves 30s repeated short bouts of 123 
activity at near maximal intensity (Wpeak ≥ 80%) interspersed with 30s rest periods, which 124 
despite its high intensity, has been successfully applied to COPD patients (10, 17, 22, 11). A 125 
representation of basic skeletal muscle adaptation promoted by aerobic/endurance, resistance 126 
and HIIT is depicted in Figure 1, originally adopted by Robinson et al. (21).  127 
Therefore, adaptations seen in COPD skeletal muscle take place in accordance with specific 128 
exercise training stimuli, thereby partially explaining the large variability in muscle 129 
adaptations seen among studies. The effect of exercise modalities in promoting COPD 130 
skeletal muscle adaptations at structural and protein metabolism levels have been recently 131 
presented in a systemic review (18). 132 
 133 
Histologically, the skeletal muscle appears uniform, but is composed by a range of 134 
heterogeneous myofibres regarding size, metabolism and contractile function. When 135 
comparing myosin-heavy-chain isoform expression, myofibres are classified into type I, type 136 
IIa, type IId/x, and type IIb fibres (23). Type I and IIa fibers exhibit high oxidative potential 137 
and IIx and IIb are primarily glycolytic. Whether endurance- or resistance-based exercise 138 
training can induce myofibre plasticity is still debatable. Certainly, COPD patients present a 139 
shift in fibre type displaying fewer type I (oxidative) fibres and greater proportion of type II 140 
(glycolytic) fibres in quadriceps muscles (24). This shifting towards glycolytic fibres is 141 
associated with increased mortality (7). Exercise training prescribed to COPD patient can 142 
only partially reverse this fiber type shifting. Proportion of fiber type I and IIa were increased 143 
mainly after HIIT and high intensive aerobic exercise (18, 25) as endurance training confers 144 
an increased oxidative profile to trained myofibers (23) . Hypertrophy of fibre type I and IIA 145 
was more widespread among different modalities of exercise training, (18), Whereas,  146 
capillary to fiber ratio adaptations were though observed across various intensities and 147 
modalities of exercise training (18).  148 
 149 
Contribution of inactivity to COPD muscle wasting 150 
 151 
Inactivity appears to be an important mechanism in the process of muscle loss in COPD, 152 
given that muscles that are active, such as the diaphragm and the adductor policis, do not 153 
exhibit atrophy in contrast to inactive muscles, such as the quadriceps (26). In experiments 154 
comparing different muscle groups in COPD patients, the characteristics exhibited by the 155 
6 
 
deltoid and the diaphragm were different compared to the quadriceps (27). Importantly, the 156 
muscles of respiration in COPD exhibit a contrary shift in fiber typing compared to the 157 
locomotor muscles, manifested by increased type I fiber distribution (28, 29). Various 158 
conditions of reduction in neuromuscular activity promoted by inactivity are known to 159 
decrease myonuclear number in atrophying muscle and impact on fibre typing. As reviewed 160 
elsewhere (30), detraining experiments in healthy individuals have shown to induce 161 
locomotor muscle adaptations that lead to increased number of muscle fibre type IIx 162 
phenotype, and attenuation of mitochondrial biogenesis (PPARs and PGC-1α) as observed in 163 
COPD patients. As described above, reassuming activity by exercise training can partially 164 
promote changes in fibre type distribution (18). However, inactivity alone does not seem to 165 
fully explain the phenomenon of muscle fibre type shifting in COPD.  166 
 167 
Mechanical stress and mitogen-activated protein kinase signalling 168 
 169 
The ability of skeletal muscles to respond to physical exercise by executing the appropriate 170 
metabolic and transcriptional response is dependent upon the cellular signal transduction 171 
through phosphorylation cascades. Multiple kinases, including AMPK, Akt and the mitogen-172 
activated protein kinases (MAPKs) are involved in the regulation of DNA transcription 173 
through the phosphorylation of nuclear transcription factors. This either enhances or inhibits 174 
the ability of transcription factors to bind DNA, affecting target gene transcription (31, 32). 175 
Three main MAPK subfamilies are activated by acute exercise in human skeletal muscle: (1) 176 
the extracellular-regulated kinase (ERK1/2), (2) the c-jun N-terminal kinase (JNK), and (3) 177 
the p38 MAPK. Activation of MAPKs regulates the transcriptional events by phosphorylation 178 
of diverse substrates localised in the cytoplasm or nucleus, including transcription factors, 179 
inducing differentiation, hypertrophy, inflammation, and gene expression (33). 180 
 181 
The MAPK p38 is a stress-activated kinase that is transiently activated in response to a 182 
strenuous range of stimuli such as physical inactivity and increased intensity of exercise 183 
training (34, 35). Activation of p38 in skeletal muscle myoblasts is related to loss a in cell 184 
autonomous self-renewal capacity (36). MAPK p38 activation is also observed during 185 
skeletal muscle immobilisation in a rat hind limb model of acute muscle wasting (37, 34). 186 
COPD are generally more inactive compared to their age-matched healthy counterparts (38). 187 
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Accordingly, ratios of phosphorylated to total level of p38 MAPK and ERK 1/2 were 188 
significantly elevated in patients with COPD compared to controls (39).  Whereas, another 189 
study have shown no differences in the ratio of phospho-p38 MAPK to total level of p38 190 
MAPK protein between COPD patients and healthy age-matched donors. Although patients 191 
with COPD present muscle wasting, discrepancies among studies would be expected as it is 192 
uncertain whether patients are actively losing muscle mass at the time of experimentation.  193 
 194 
Major signaling pathways involved in the control of exercise training induced skeletal 195 
muscle adaptations 196 
 197 
Endurance- and resistance-based modalities of exercise are controled by two major signaling 198 
pathways regulating mitochondria biogenesis and hypertrophy respectively, as depicted in 199 
Figure 2.  200 
 201 
The regulation of mitochondrial biogenesis by endurance-based exercise converge from 202 
activation of the cascades AMPK and p38 upregulating PGC-1α. When compared to healthy 203 
controls, mitochondria density is lower in quadriceps muscle of COPD patients, presenting 204 
lower expression of peroxisome proliferator-activated receptors (PPARs), PPAR-γ co-205 
activator 1α (PGC-1α) and mitochondrial transcription factor (TFAM) in cachectic COPD 206 
(40). In patients with COPD, exercise enhances the decrease in mitochondria DNA content of 207 
skeletal muscle and the expression of PGC-1α mRNA seen in healthy subjects, probably due 208 
to oxidative stress (41). 209 
 210 
In contrast, resistance training is described to stimulate the signaling pathways responsible 211 
for muscle hypertrophy (12, 13). The activation of mTOR and IGF-I appears to be important 212 
in this process. To restore muscle mass via regular exercise training, protein synthesis should 213 
exceed protein breakdown over an extended period. Hypertrophy of skeletal muscle as result 214 
of resistance exercise training is strongly associated with the degree of mTOR activation, 215 
ribosomal protein S6K (p70S6K) phosphorylation and downstream targets (42). Contraction-216 
induced p70S6K activation is dependent on mTOR activation, which increases protein 217 
translation and inhibits protein degradation via inhibition of both ubiquitin proteasome (43, 218 
32, 44) and autophagy-lysosome pathways (45, 46). mTOR activation is critical to load-219 
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induced muscle growth, as demonstrated by the attenuation of hypertrophy responses and 220 
protein synthesis by the mTOR inhibitor, rapamycin (43).  221 
 222 
We and others have described that Akt/mTOR pathway is downregulated in skeletal muscle 223 
of patients with COPD compared to healthy subjects (10). HIIT promotes the activation of 224 
the Akt/mTOR pathway in skeletal muscle only in COPD patients with preserved muscle 225 
mass compared to aged matched controls. Some studies suggest that hypoxemia 226 
characteristically observed in more severe cachectic COPD patients, is associated with 227 
resistance of skeletal muscle activation of the Akt/mTOR pathway (16). Exercise training in 228 
hypoxemic patients with COPD was not capable to promote muscle fibre hypertrophy and 229 
activation of the Akt/mTOR pathway as compared to normoxemic COPD patients (16). Both 230 
in vitro C2C12 myotubes cultured in normoxic and hypoxic conditions and mice models of 231 
hypoxia suggest that the response of the Akt/mTOR pathway to exercise could be 232 
compromised in hypoxemic patients (16, 47). Therefore, impairment of skeletal muscle 233 
hypertrophy commonly linked to the severity of the disease is associated with the magnitude 234 
of muscle wasting, the degree of hypoxia, or both. Interestingly, induced expression of the 235 
adaptive response of hypoxia HIF-1 responsive RTP801 (DDIT4) is observed only in trained 236 
COPD and not in healthy subjects (48).  237 
 238 
mTOR regulates the mechanisms of protein synthesis at several levels (e.g. translation 239 
capacity, translation efficiency) through increases of translation of specific mRNAs, which 240 
culminates in skeletal muscle fibre enlargement. mTOR exists as part of two multi-protein 241 
complexes: i) mTORC1, which contains raptor and confers rapamycin sensitivity, is required 242 
for signalling to p70S6K and 4E-BP1, whereas ii) mTORC2, which contains rictor and is 243 
rapamycin insensitive, is required for signalling to Akt-FOXO (49). The effect of mTOR 244 
activity on downstream regulators of protein synthesis is principally achieved through a 245 
contraction-induced regulation of mTORC1 (50).  246 
 247 
Early work on adaptive hypertrophy has focused on the (transient) post exercise rise in blood-248 
borne anabolic hormones, such as growth hormone and insulin-like growth factor-I (IGF-I), 249 
and the consequent activation of the muscle protein synthesis of a signalling cascade 250 
(phosphoatidylinositol 3-kinase (PI3K)-Akt-mTOR) by IGF-I interaction with insulin and 251 
IGF receptors (51). Recently, the muscle growth paradigm has shifted focus to IGF-I-252 
independent mechanisms of mTOR activation and adaptive hypertrophy through mechano-253 
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sensory regulation (50). Nutrient-dependent regulation of muscle growth is achieved through 254 
insulin- and Akt-dependent activation of the mTOR pathways. These pathways operate 255 
synergistically causing muscle growth and can be augmented by appropriate nutritional 256 
intake such as post exercise carbohydrate and amino acid ingestion or increased dietary 257 
protein (52). Therefore, IGF-I is involved not only in hypertrophy but also in promoting 258 
myogenesis and muscle regeneration.  259 
 260 
Regulation of skeletal muscle protein synthesis promoting myogenesis and muscle 261 
regeneration 262 
 263 
Skeletal muscle hypertrophy is achieved by both positive protein balance and fusion of 264 
satellite cells to myofibres (Figure 1). It is a process that involves (1) accretion of protein in 265 
various cellular compartments via mechanosensitive signalling pathways that drive 266 
translation, and (2) the activation and recruitment of resident muscle stem cell (satellite cells) 267 
that differentiate to fusion-competent myoblasts (53, 54). Regulation of protein translation 268 
and synthesis promotes accretion, whereas activation and incorporation of satellite cells 269 
facilitates the addition of myofibrils to the muscle. 270 
 271 
Myogenesis and muscle regeneration depend on critical steps for activation of quiescent 272 
satellite cell, proliferation, migration, differentiation, fusion and maturation. Fusion of a 273 
satellite cell to an existent myofibre results in an increase in the number of myonuclei, and 274 
thus the available total amount of genetic machinery for protein production (54). The average 275 
number of myonuclei per muscle fibre of non-cachectic COPD is twice as high compared to 276 
controls, indicating higher capacity of protein metabolism necessary for maintenance of 277 
muscle mass. Quiescent satellite cells are essential to replenishment of myonuclei pool. As 278 
satellite cells replicate throughout lifespan, telomeres are shortened. Telomere shortening is a 279 
marker of senescence. COPD patients, despite the observation that satellite cells numbers are 280 
unaltered in the limb muscle compared to controls, satellite cells present shorter telomeres. A 281 
fact suggesting exhausted muscle regenerative capacity, compromising the maintenance of 282 
muscle mass (55).  283 
 284 
Satellite cells myogenic regulatory factors (MRF) and myostatin play important roles in 285 
myogenesis and muscle regeneration. mRNA and protein expression of the myogenic 286 
differentiation factor D (MyoD), involved in the proliferation process, has been shown to 287 
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increase in the skeletal muscle of non-cachectic COPD patients after HIIT, but no changes 288 
were observed in cachectic COPD patients after HIIT (10). MyoD protein expression was 289 
also increased after resistance training with or without nutritional supplementation in patients 290 
and healthy controls (56). mRNA expression of MRF myogenin, involved in the 291 
differentiation process, was not different between a resistance training group and a control 292 
group, while addition of testosterone supplementation to resistance training increased 293 
myogenin mRNA expression compared to the control group (57). mRNA and protein 294 
expression of the myogenic inhibiting factor myostatin, showed no significant change after 295 
resistance exercise training neither in patients nor in healthy controls, or after combined 296 
aerobic and resistance training (56, 16). After HIIT however, non-cachectic COPD patients 297 
showed a significant decrease in mRNA and protein expression of myostatin, while in 298 
cachectic COPD patients HIIT did not significantly alter mRNA or protein myostatin 299 
expression (10). In addition, mRNA expression of a negative regulator of cell proliferation 300 
Kruppel-like factor 10 (KLF11) was increased after aerobic training in patients, but not in 301 
healthy controls (48).  302 
 303 
The IGF-I system plays an important role in the regulation of muscle cell growth, muscle cell 304 
proliferation and muscle cell survival (58, 59). After HIIT, mRNA expression of both IGF-I 305 
and the mechano-growth factor (MGF), an isoform of IGF-I, significantly increases. Both 306 
cachectic and non-cachectic COPD patients have shown enhanced MGF mRNA expression 307 
post-training (10). However, no significant increase in protein expression of IGF-I and MGF 308 
expression was observed in cachectic COPD patients in comparison to non-cachectic. Other 309 
exercise protocols such as combined aerobic and resistance training were not capable to 310 
increase the expression of the IGF-I variants (16). However, testosterone supplementation 311 
was found to increase the levels of IGF-I and MGF protein expression in COPD patients after 312 
resistance training (57).  313 
 314 
Exercise induced changes in gene expression 315 
Comparing gene transcription among different modalities of exercise in healthy individuals, 316 
Robinson et al (21) found that HIIT promotes a stronger increase in gene transcripts than 317 
other modalities of exercise tested, particularly in older adults.  318 
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Skeletal muscle gene expression from COPD after high intensity aerobic exercise training 319 
compared to age-matched controls were analysed using Genechip Array (48). High aerobic 320 
exercise training induced up-regulation of quantitatively significantly fewer genes in the 321 
skeletal muscle of COPD (107 were upregulated and 124 were downregulated) compared 322 
with healthy controls (258 were upregulated and 315 were downregulated). Qualitatively, 323 
genes associated with protein degradation, such as oxidative stress, ubiquitin proteasome, and 324 
COX pathways were distinctly induced only in patients with COPD, potentially reflecting the 325 
specific molecular response of the muscle to exercise in COPD, thereby suggesting additional 326 
operating mechanisms for exercise limitation in these patients. Whether exercise training can 327 
sufficiently enhance muscle hypertrophy to outstrip muscle wasting in COPD patients with 328 
substantial muscle loss, remains an unresolved issue. 329 
 330 
Regulation of skeletal muscle protein breakdown 331 
 332 
Muscle tissue homeostasis is maintained by a tight and complex balance between protein 333 
synthesis and degradation. Protein metabolism turnover is a dynamic process balancing 334 
protein synthesis and breakdown. Muscle wasting due to an increase in protein breakdown is 335 
a feature shared among many acute and chronic disease entities as well as healthy ageing.  336 
 337 
Muscle wasting has primarily been attributed to increased protein degradation. Protein 338 
degradation in COPD patients peripheral muscles takes place through four proteolytic 339 
systems, including the ubiquitin-proteasome (UP) pathway, the calpain pathway, the caspase 340 
pathway, and the autophagy-lysosome (AL) pathway as reviewed elsewhere (60).  341 
 342 
Exercise has been found to stimulate mitogen activated protein kinases MAPK-9 and MAPK 343 
activated protein kinase 3 (MAPKAPK-3) in COPD compared to healthy controls (48). The 344 
MAPK pathway, in turn activates forkhead transcription factors, involved in muscle protein 345 
degradation. When inflammatory response to exercise is limited, the muscle recovers in a 346 
timely manner; however, persistent systemic inflammation described in COPD, may be 347 
associated with muscle wasting and adversely impact on muscle protein metabolism (61). 348 
Numerous pathological indicators in COPD, namely systemic inflammation, hypoxia and 349 
oxidative stress most likely trigger catabolic processes in skeletal muscle, that are mediated 350 
by transcriptional regulators including nuclear factor kappa-light-chain-enhancer of activated 351 
B cells (NF-kB) and forkhead box O transcription factors (FOXOs). The activity of NF-kB is 352 
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increased in COPD compared with healthy age-matched individuals (18, 62, 10, 22) and in 353 
particular in patients  with muscle wasting compared to those without muscle wasting (63, 354 
10). FOXO mRNA and protein expression is increased in patients with COPD (64-67, 62). 355 
The expression of FOXO-1 may be associated with physical inactivity as protein expression 356 
is increased in lower limbs compared to respiratory muscles in COPD patients, but not in 357 
healthy controls (68). Increased catabolic signaling through FOXO and NF-kB activation 358 
may induce gene expression of key factors in both ubiquitin proteasome system (UPS) (69, 359 
32) and the autophagy lysosome pathways (45). 360 
 361 
Concluding remarks 362 
Exercise training promotes a range of beneficial adaptations in the skeletal muscle including 363 
increased capilarization, fibre type plasticity, hypertrophy and function. All these adaptations 364 
are a result of exercise stimuli that challenges muscle homeostasis by activating networks of 365 
signalling molecules. Activation of kinases and pre-transcriptional regulation occurs rapidly 366 
during exercise and recovery, whereas protein transcription is subsequently regulated. 367 
Intensity, duration, and mode of the exercise stimuli collectively contribute to the relative 368 
activation and the magnitude of activated pathways and downstream targets (12, 13). All 369 
these parameters have to be considered when designing exercise studies, so results are 370 
comparable and can advance knowledge in the area. Future studies on the molecular 371 
mechanisms of exercise induced satellite cell myogenic capacity in COPD patients are 372 
fundamental for designing pharmacological and exercise training interventions aiming to 373 
address resistance to exercise-induced adaptations. 374 
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Figure 1: COPD skeletal muscle adaptations to various modalities of exercise training. 568 
Exercise training is a powerful stimulus producing hypertrophy and regeneration of muscle 569 
by increased protein metabolism and fusion of satellite cells to existent myofiber. Endurance- 570 
and resistance-based exercise training programmes are characterised as stimuli capable for 571 
increasing oxidative capacity and hypertrophy, respectively. Skeletal muscle adaptations 572 
observed from combined endurance/resistance as well as high intensity interval training 573 
reflect a wider range of stimuli. (The Figure was originally adopted by Robinson et al. (21) 574 
and subsequently modified by authors). 575 
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Figure 2: Diagram of the major signalling pathways involved in the control of skeletal muscle 585 
hypertrophy and mitochondrial biogenesis. Voluntary exercise training activate 586 
kinases/phosphatases to mediate a specific exercise-induced signal. The cross talk among the 587 
numerous signalling pathways activated and the multiple site regulation produces a high 588 
sensitive and complex transduction network.  589 
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